Search

everythinglearnresearchcommunity

for

Search:↓

Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.

Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.

Targeting specific T cells may help treat alopecia areata.

Special cells can help regrow hair in alopecia areata.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

γδTregs may help treat autoimmune diseases like alopecia areata by promoting hair regrowth and reducing immune attacks.

CAR-T therapy offers hope for children with hard-to-treat blood cancers.

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

CD8+ T cells play a key role in graft-versus-host disease in certain mice models.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

HTLV-1-associated lichenoid dermatitis (HALD) is linked to an immune response against HTLV-1-infected cells.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Gamma/delta T cells help defend skin against heavy metals.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Transcutaneous vaccination using nanoparticles can enhance immune responses and reduce basal cell carcinomas.

Malt1 protease is essential for regulatory T cell function and could be targeted to boost antitumor immunity.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

ITK inhibitors may effectively treat alopecia areata.

ILC1-like cells can cause alopecia areata by disrupting hair follicle immunity, suggesting a new treatment approach.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

T cells with memory features grow in number and gather around hair follicles when there are not enough immune cells.

Hair follicles produce IL-7, which is essential for certain skin lymphoma cells to survive.

Cats likely have a reactive skin condition, while dogs may have a more complex, possibly cancerous one.

Certain immune cells may cause hair loss by reacting to stressed hair follicles.